Freedom of Information request on the Public Assessment Report (PAR) for Ralvo 700mg medicated plaster (FOI 21/556)
Published 28 June 2021
27th May 2021 FOI 21/556
Dear
Thank you for your email your email enquiring about the Public Assessment Report (PAR) for Ralvo 700mg medicated plaster (lidocaine - PL 21727/0075), this product was granted by an abridged simple (Article 10c) decentralised procedure (UK/H/6362/001/DC) on 22 February 2017. The PAR that is available for the other product granted in the same assessment, Lonioban 700mg medicated plaster (lidocaine - PL 21727/0073; UK/H/6338/001/DC), does have a PAR published – please see the link below: https://mhraproducts4853.blob.core.windows.net/docs/1f99163fc105fe1d9f300b1812c608ac5e139a1c
We will add the product details for Ralvo 700mg medicated plaster (PL 21727/0075) to the above PAR and republish this as soon as possible. We apologise for this oversight.
If you are dissatisfied with the handling of your request, you have the right to ask for an internal review.
Internal review requests should be submitted within two months of the date you receive this response and addressed to: info@mhra.gov.uk .
Please remember to quote the reference number above in any future communications.
Please note, due to the ongoing Covid-19 situation, we are not able to accept delivery of any documents or correspondence by post or courier to any of our offices.
If you were to remain dissatisfied with the outcome of the internal review, you would have the right to apply directly to the Information Commissioner for a decision. Please bear in mind that the Information Commissioner will not normally review our handling of your request unless you have first contacted us to conduct an internal review. The Information Commissioner can be contacted at:
Information Commissioner’s Office Wycliffe House Water Lane Wilmslow Cheshire SK9 5AF
Yours sincerely, MHRA Customer Service Centre Medicines and Healthcare products Regulatory Agency 10 South Colonnade, Canary Wharf, London E14 4PU